BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition - 2Find the Excellence of Old style Expressive dance: Encountering the Effortlessness and Polish of Dance
- 3Greece eyes migrant repatriation centres outside the EU
- 4Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- 5Renewables cover over 50% of German electricity consumption in Q1
- Passover under fire: Israelis balance fatigue with cautious hope after month of war
- Manual for Tracking down the Mysterious Cascades in China
- Italian authorities detain civilian rescue ship, German NGO says
- Home Security Frameworks with Shrewd Elements
- 'Dancing with the Stars' semifinals: How to watch Episode 10 tonight, where to stream, who's left and more
- The Effect of Online Organizations on Society: Beating the Difficulties
- 2025 Arctic League telethon raises more than $39k
- Figure out How to Put resources into Lab Precious stones
- Is Iran using cryptocurrencies to circumvent sanctions?
